BAXERNA

BAXERNA (www.baxerna.eu) is an EU-funded project that aims to develop next-generation mRNA vaccines against devastating bacterial infections like tuberculosis. The project consortium is led by researchers from VIB and UGent and includes multiple prominent European institutes, along with several innovative biotech companies. Together, these partners are developing effective and affordable vaccines using cutting-edge techniques, including immunopeptidomics, artificial intelligence, and nanomedicine. The top vaccine candidate against tuberculosis will be tested in a phase I clinical trial at Ghent University Hospital. With the combined expertise of its consortium, BAXERNA promises to revolutionize vaccine development against intractable bacterial pathogens.